Navigation Links
Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
Date:9/1/2008

NATICK, Mass. and MUNICH, Germany, Sept. 1 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced one-year data from its landmark SYNTAX trial comparing percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System to contemporary coronary artery bypass graft (CABG) surgery. The overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI). The Company made the announcement at the annual European Society of Cardiology meeting in Munich, Germany.

The SYNTAX trial is the first randomized, controlled clinical trial to compare PCI using drug-eluting stents (DES) to CABG in patients with left main disease and three-vessel disease. These patient groups are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior DES clinical trials. The goal of the trial is to expand the body of knowledge of PCI use and help inform physicians on appropriate treatment options for the sickest patients.

"For PCI patients to do so well with such complex anatomy and advanced disease is extraordinary," said Keith Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "These patients, the majority of whom are normally treated with surgery, are the most challenging group ever studied in a DES clinical trial."

The SYNTAX trial also demonstrated a significant decrease in the rate of stroke for patients treated with PCI as compared to CABG.

"The significant difference in the stroke rate between the PCI and the CABG groups is an important finding," said Dr. Dawkins. "Physicians and their patients will
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioStorage Technologies Serves as Repository for Landmark Study of Coronary Artery Disease
2. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
3. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
4. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
5. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
10. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
11. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... Gallus BioPharmaceuticals , LLC, ... manufacturing organization (CMO) announced today that it has ... company focused on the development of innovative approaches ... anti-prostate specific membrane antigen (PSMA) monoclonal antibody used ... the agreement the antibody will be produced in ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
(Date:8/20/2014)... licensed to biotechnology firms has revealed early bottlenecks ... roadblocks, the researchers suggest that better communication of ... lead to faster commercialization down the road. , ... in university laboratories and licensed to biotechnology firms. ... have a high failure rate. But a new ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Two physicists from The University of Manchester who discovered ... for their work. , Professor Andre Geim FRS and ... Nanotechnology have been awarded the prestigious Europhysics Prize for ... reveal its remarkable electronic properties. , Graphene is a ...
... Inc.,(Nasdaq: MEDX ) announced today that it is ... at 9:10 a.m. Eastern Time on,Thursday, September 4, 2008. ... in the Investor Relations section of the Medarex website ... will be available,following the event., About Medarex, ...
... presentations included Resverlogix data, TSX Exchange Symbol: ... Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased to ... pertaining to its lead compound,RVX-208, at the European ... titled "RVX-208 a novel small molecule that increases,apolipoprotein ...
Cached Biology Technology:Graphene pioneers follow in Nobel footsteps 2Medarex to Present at the Thomas Weisel Partners Healthcare Conference 2ApoA-I Data Presented at European Society of Cardiology Congress 2
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
(Date:8/21/2014)... that has implications for life in other extreme environments, ... system, LSU Associate Professor of Biological Sciences Brent Christner ... or NSF, this week published a paper confirming that ... 800 meters (2600 feet) beneath the surface of the ... that more than 400 subglacial lakes and numerous rivers ...
(Date:8/21/2014)... international standards process, will be available soon and will ... published in the OnlineFirst version of Nutrition in ... of the American Society for Parenteral and Enteral Nutrition ... of misconnection that can be harmful and even fatal ... join medical devices, components, and accessories to deliver fluids ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4New feeding tube connectors will improve patient safety 2
... cities is often an overlooked resource. Years of manufacturing or ... scare residents away from using the land. As the local ... desire to grow food in cities with the fear that ... 10:35 am, Kristen McIvor of the Pierce Conservation District will ...
... STATION Dr. Xiuren Zhang, a biochemist and ... has been awarded almost $1.3 million from the National ... and plant stem cells, which ultimately could help breed ... science foundation,s CAREER program, which is given in "support ...
... Microbial fuel cells, chemical sensors for your iPhone, ... faster-charging batteries, safer nuclear power, and new crime scene ... on the science of materials, interfaces, and processing. Detailed ... AVS 60th International Symposium & Exhibition will take place ...
Cached Biology News:Fostering community gardens in an area with historic soil contamination 2AgriLife researcher Xiuren Zhang receives National Science Foundation CAREER grant 2AVS science symposium in Long Beach Oct. 27 -- Nov. 2 2
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Pronase Reagent...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: